INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $25,014,496 | -35.3% | 480,273 | -21.4% | 0.02% | -33.3% |
Q2 2023 | $38,676,860 | -7.8% | 610,915 | -21.1% | 0.02% | -14.3% |
Q1 2023 | $41,936,959 | +176.5% | 774,540 | +170.2% | 0.03% | +154.5% |
Q4 2022 | $15,167,289 | +43.8% | 286,689 | -36.8% | 0.01% | +37.5% |
Q3 2022 | $10,550,540 | -1.7% | 453,482 | +141.1% | 0.01% | +14.3% |
Q2 2022 | $10,731,000 | +38.1% | 188,051 | +48.1% | 0.01% | +75.0% |
Q1 2022 | $7,772,000 | +0.5% | 127,001 | -14.1% | 0.00% | +33.3% |
Q4 2021 | $7,730,000 | +42.0% | 147,866 | +1.2% | 0.00% | +50.0% |
Q3 2021 | $5,445,000 | +1.0% | 146,165 | +10.7% | 0.00% | 0.0% |
Q2 2021 | $5,391,000 | +35.3% | 132,085 | +12.7% | 0.00% | 0.0% |
Q1 2021 | $3,984,000 | +167.6% | 117,223 | +150.6% | 0.00% | +100.0% |
Q4 2020 | $1,489,000 | +169.7% | 46,783 | +33.7% | 0.00% | – |
Q3 2017 | $552,000 | +26.9% | 35,000 | 0.0% | 0.00% | – |
Q2 2017 | $435,000 | – | 35,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |